Compare Abeona Therapeutics Inc (ABEO) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Lockheed Martin Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Lockheed Martin Corporation trades at $528.81 (market cap $123.44B). The key difference: Lockheed Martin Corporation is far larger — about 330.7× Abeona Therapeutics Inc's market cap, and Lockheed Martin Corporation pays a 2.58% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | LMT | |
|---|---|---|
Market Cap | $373.32M | $123.44B |
Sector | Health | Industrials |
52-Week High | $7.23 | $676.70 |
52-Week Low | $4.17 | $410.74 |
Enterprise Value | $228.22M | $142.24B |
Dividend Yield | — | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Lockheed Martin (LMT) trades at $535.38, down 1.89% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $627.50. Recent financials show revenue growth to $75.05B in 2025, though net income margin declined to 6.38%. The company announced a $3.45B acquisition of Ultra Maritime to expand naval defense capabilities, and a dividend of $3.45 is scheduled for payment in June 2026.
LMT offers stability through government contracts and dividend growth, but faces risks from execution on recent acquisitions and margin pressure. Analyst sentiment is positive with 57% buy ratings, yet recent earnings misses and rising debt levels warrant caution. The stock presents a long-term opportunity in defense, balanced by near-term operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
